Regeneron’s stock value tumbled 11.8% during premarket trading Monday following news that the pharmaceutical company’s experimental cancer therapy failed to achieve its primary objective in a late-stage clinical trial involving patients with advanced melanoma.
The biotechnology firm’s combination therapy using fianlimab-cemiplimab did not demonstrate statistically significant improvement in progression-free survival (PFS), which measures the duration patients live without experiencing worsening of their advanced melanoma condition.
Advanced melanoma represents a severe type of skin cancer that has the potential to metastasize quickly throughout the body, creating significant treatment challenges.
The clinical trial evaluated fianlimab combined with Regeneron’s already-approved medication cemiplimab, marketed as Libtayo, as an initial treatment option.
While the experimental combination therapy demonstrated a numerical enhancement of 5.1 months in median PFS compared to Merck’s Keytruda, this improvement failed to achieve statistical significance.
Evercore analyst Cory Kasimov characterized the outcome negatively, stating “These results are the worst-case scenario,” while noting that although the fundamental impact remains relatively contained currently, market sentiment would probably deteriorate additionally.
